AcquisitionsApr 13, 2026, 05:02 PM
XORTX Closes $3M Acquisition of Kidney Disease Program VB4-P5
AI Summary
XORTX Therapeutics Inc. has finalized the acquisition of the Vectus kidney anti-fibrotic asset for an aggregate price of US$3.0 million. The acquisition includes VB4-P5, a novel chemical entity and its associated intellectual property, which is currently at the pre-IND stage of development. This program targets both rare and prevalent forms of kidney disease, aligning with XORTX's strategic focus and expanding its pipeline into areas with substantial unmet medical need.
Key Highlights
- Acquired Vectus kidney anti-fibrotic asset for $3.0 million.
- Issued 154,544 common shares and 692,150 pre-funded warrants.
- VB4-P5 targets rare and prevalent kidney disease, currently pre-IND stage.
- Kidney disease affects 35-37 million in US, addressable market >10 million.